Howland Capital Management LLC Purchases 4,616 Shares of Johnson & Johnson $JNJ

Howland Capital Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 6.6% during the third quarter, Holdings Channel.com reports. The firm owned 74,668 shares of the company’s stock after acquiring an additional 4,616 shares during the quarter. Howland Capital Management LLC’s holdings in Johnson & Johnson were worth $13,845,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. SOA Wealth Advisors LLC. lifted its holdings in shares of Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after purchasing an additional 53 shares in the last quarter. Ethos Financial Group LLC raised its position in Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares during the last quarter. Heritage Oak Wealth Advisors LLC lifted its stake in Johnson & Johnson by 3.5% during the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares during the period. Lifestyle Asset Management Inc. grew its stake in shares of Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock worth $312,000 after acquiring an additional 56 shares during the period. Finally, Wynn Capital LLC raised its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after purchasing an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Bank of America lifted their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $213.33.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts are becoming more constructive on JNJ heading into 2026, citing improving fundamentals and durable cash flow that support the dividend and valuation. Analysts Turn More Constructive on Johnson & Johnson
• Positive Sentiment: Zacks highlights J&J alongside other large names and notes strong pharma and MedTech momentum, which could underpin revenue growth and investor confidence heading into earnings. Zacks Investment Ideas feature highlights
• Positive Sentiment: JNJ continues to be recommended as a dividend holding in retail investor lists, reinforcing demand from income‑oriented investors given its yield and payout consistency. 3 Dividend Stocks to Own
• Neutral Sentiment: Multiple pre‑earnings analyst pieces (TipRanks, Zacks) note JNJ’s Q4 revenue expectations (~$24.16B, roughly +7% YoY) and discuss positioning strategies for investors who want exposure but want to limit risk ahead of the print. Is JNJ Stock a Buy Ahead of Q4?
• Neutral Sentiment: Zacks’ Q&A on buy/hold/sell frames JNJ as a mixed case: strong product momentum but headline risk into the report — useful context but not a direct catalyst. Should You Buy, Sell or Hold J&J Ahead of Q4?
• Negative Sentiment: Seeking Alpha warns J&J is tempering expectations after a sizable 2025 downgrade, highlighting margin and growth pressures that could weigh on sentiment if management echoes lowered guidance. Tempering Expectations After A Massive 2025
• Negative Sentiment: Zacks and other previews call out near‑term headwinds: Stelara biosimilar competition and China market pressures that could blunt top‑line growth and weigh on the print. Buy/Sell/Hold Preview
• Negative Sentiment: Bank of America maintained a Hold rating, signaling limited near‑term upside in analyst coverage and possibly contributing to cautious positioning. Bank of America Sticks to Hold

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $218.81 on Tuesday. The stock has a market cap of $527.18 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock’s fifty day moving average is $206.43 and its 200 day moving average is $187.62. Johnson & Johnson has a one year low of $141.50 and a one year high of $220.11.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.